Silent epidemic of liver diseases. Innovative study at IIMCB
Over 25% of adults have metabolic-associated steatotic liver disease (MASLD), though they often remain unaware of it. This disease can develop silently over many years without clear symptoms. Early diagnosis allows individuals to take preventive action and avoid complications. There is now an opportunity to evaluate the state of the liver and gut microbiota free of charge, while helping researchers develop new diagnostic methods. The International Institute of Molecular and Cell Biology in Warsaw (IIMCB) is conducting a study funded by the Medical Research Agency, recruiting 400 participants.
New biomarkers: towards more effective diagnosis
MASLD is one of the most common metabolic diseases, but often it is detected by chance. Researchers at IIMCB aim to change this by identifying biomarkers that can facilitate earlier and more effective detection and treatment.
“Metabolic-associated steatotic liver disease is increasingly better understood, yet effective early diagnostic methods are still lacking. Our study focuses on identifying biomarkers that could allow precise diagnosis at an early stage,” says Dr. Aleksandra Kołodziejczyk, Head of the Laboratory of Cellular Genomics at IIMCB and project leader. “By participating in the study, individuals will not only gain valuable information about their liver condition but also support the development of diagnostic tools that could significantly enhance future monitoring and treatment of this disease.”
Comprehensive diagnostics at no cost
Participants will receive advanced diagnostic tests with an approximate market value of PLN 3,000 (approx. EUR 700). These include liver elastography – a modern, painless method of assessing liver health – and detailed blood analyses, including lipid profiles, glucose levels, and inflammatory markers.
One of the most valuable components of the study is the most comprehensive gut microbiota analysis available on the market, valued at approximately PLN 2,500 (approx. EUR 585). This unique opportunity allows participants to understand their microbiota composition and its impact on metabolic health. Increasing research indicates the key role gut bacteria play in digestion, blood sugar regulation, and inflammatory responses. “Through microbiota analysis, we can determine which bacteria predominate in the gut and assess their potential influence on metabolism and liver health,” explains Dr. Kołodziejczyk.
The study's results will provide participants with insights into their body's functioning, aiding them in modifying their diet and lifestyle. The gut microbiota composition affects metabolic health, sugar metabolism, energy levels, and even mood.|
Who can participate?
The study invites individuals from Warsaw aged 35-65, including healthy participants and those with overweight, diabetes, insulin resistance, or hypertension.
Eligible participants must have communicative proficiency in Polish sufficient to complete registration formalities and participate in medical procedures in an informed manner. Additionally, they should not have undergone antibiotic treatment within the last six months.
How to enroll?
Recruitment is ongoing, but spots are limited. Interested individuals can apply through the form available on the project website:
The study is conducted in Warsaw, offering participants the chance to monitor their health and contribute to research potentially transforming metabolic disease diagnostics.
The project "Identification of biomarkers for metabolic-associated steatotic liver disease" is funded under the National Recovery and Resilience Plan, Component D – Effectiveness, accessibility, and quality of the healthcare system, Investment D3.1.1 – Comprehensive development of research in medical and health sciences, with funds provided by the Medical Research Agency through a competition for research institutions to conduct applied biomedical research (2024/ABM/03/KPO).